{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:54:48Z","timestamp":1782921288375,"version":"3.54.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s15010-026-02798-8","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T03:25:39Z","timestamp":1776828339000},"page":"1573-1581","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessing fluoroquinolone resistance in Mycobacterium tuberculosis using nanopore sequencing: concordance with established diagnostic methods"],"prefix":"10.1007","volume":"54","author":[{"given":"Rashmi","family":"Ratnam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parul","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhoopendra","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manu","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urmila","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram Awadh Singh","family":"Kushwaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"2798_CR1","unstructured":"Global Tuberculosis Report 2023."},{"key":"2798_CR2","doi-asserted-by":"publisher","first-page":"5155","DOI":"10.1128\/AAC.00831-16","volume":"60","author":"KJ Aldred","year":"2016","unstructured":"Aldred KJ, Kerns RJ, Osheroff N. Fluoroquinolone interactions with Mycobacterium tuberculosis DNA gyrase. Antimicrob Agents Chemother. 2016;60:5155\u201364. https:\/\/doi.org\/10.1128\/AAC.00831-16.","journal-title":"Antimicrob Agents Chemother"},{"key":"2798_CR3","volume-title":"WHO consolidated guidelines on drug-resistant tuberculosis treatment","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020."},{"key":"2798_CR4","volume-title":"WHO operational handbook on tuberculosis: module 3: diagnosis: rapid diagnostics for tuberculosis detection, 2021 update","author":"World Health Organization","year":"2021","unstructured":"World Health Organization. WHO operational handbook on tuberculosis: module 3: diagnosis: rapid diagnostics for tuberculosis detection, 2021 update. Geneva: World Health Organization; 2021."},{"key":"2798_CR5","volume-title":"Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB): policy update","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB): policy update. Geneva: World Health Organization; 2016."},{"key":"2798_CR6","volume-title":"Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis. 2nd ed. Geneva: World Health Organization; 2018.","edition":"2"},{"key":"2798_CR7","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1128\/JCM.02741-12","volume":"51","author":"L Rigouts","year":"2013","unstructured":"Rigouts L, Gumusboga M, de Rijk WB, Nduwamahoro E, Uwizeye C, de Jong B, et al. Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isolates with specific rpoB mutations. J Clin Microbiol. 2013;51:2641\u20135.","journal-title":"J Clin Microbiol"},{"key":"2798_CR8","volume-title":"Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance","author":"World Health Organization","year":"2021","unstructured":"World Health Organization. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. Geneva: World Health Organization; 2021."},{"key":"2798_CR9","first-page":"e01712","volume":"65","author":"TJ Opperman","year":"2021","unstructured":"Opperman TJ, Nguyen Q, Walker J, Adinolf S, Kaplan E, Nguyen L, et al. Phenotypic and genotypic characterization of fluoroquinolone resistance in Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother. 2021;65:e01712-e1720.","journal-title":"Antimicrob Agents Chemother"},{"key":"2798_CR10","doi-asserted-by":"publisher","first-page":"331","DOI":"10.4103\/ijmy.ijmy_139_24","volume":"13","author":"S Sengupta","year":"2024","unstructured":"Sengupta S, Jain P, Ratnam R, et al. Agreement between phenotypically detected Linezolid resistance and mutations in rrl and rplC genes of Mycobacterium tuberculosis isolates using Nanopore sequencing. Int J Mycobacteriol. 2024;13:331\u20136. https:\/\/doi.org\/10.4103\/ijmy.ijmy_139_24.","journal-title":"Int J Mycobacteriol"},{"key":"2798_CR11","doi-asserted-by":"publisher","first-page":"14232","DOI":"10.1038\/s41598-021-93379-0","volume":"11","author":"C Mariner-Llicer","year":"2021","unstructured":"Mariner-Llicer C, Pardo-S\u00e1nchez R, et al. Accuracy of an amplicon-sequencing nanopore approach for detecting drug resistance in Mycobacterium tuberculosis. Sci Rep. 2021;11:14232. https:\/\/doi.org\/10.1038\/s41598-021-93379-0.","journal-title":"Sci Rep"},{"key":"2798_CR12","first-page":"882555","volume":"13","author":"F Minhaj","year":"2022","unstructured":"Minhaj F, Gupta A, Singh PK, Singh UB, Singh S, Sharma P, et al. Evaluation of targeted nanopore sequencing for detection of drug resistance in Mycobacterium tuberculosis clinical isolates. Front Microbiol. 2022;13:882555.","journal-title":"Front Microbiol"},{"key":"2798_CR13","doi-asserted-by":"publisher","first-page":"e593","DOI":"10.1016\/S2666-5247(22)00301-9","volume":"4","author":"MB Hall","year":"2023","unstructured":"Hall MB, Sleet K, et al. Evaluation of nanopore sequencing for Mycobacterium tuberculosis drug susceptibility testing and outbreak investigation: a genomic analysis. Lancet Microbe. 2023;4:e593\u2013601. https:\/\/doi.org\/10.1016\/S2666-5247(22)00301-9.","journal-title":"Lancet Microbe"},{"key":"2798_CR14","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12864-024-11128-7","volume":"25","author":"C Tang","year":"2024","unstructured":"Tang C, Chen J, et al. High-throughput nanopore targeted sequencing for efficient drug resistance assay of Mycobacterium tuberculosis. BMC Genomics. 2024;25:174. https:\/\/doi.org\/10.1186\/s12864-024-11128-7.","journal-title":"BMC Genomics"},{"key":"2798_CR15","volume-title":"Technical consultation on next-generation sequencing technologies for drug-resistant tuberculosis detection","author":"World Health Organization","year":"2023","unstructured":"World Health Organization. Technical consultation on next-generation sequencing technologies for drug-resistant tuberculosis detection. Geneva: World Health Organization; 2023."},{"key":"2798_CR16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.4103\/ijmr.IJMR_1220_17","volume":"149","author":"R Sharma","year":"2019","unstructured":"Sharma R, Sharma SK, Singh BK, Mittal A, Kumar P. High degree of fluoroquinolone resistance among pulmonary tuberculosis patients in New Delhi, India. Indian J Med Res. 2019;149:62\u20136.","journal-title":"Indian J Med Res"},{"key":"2798_CR17","doi-asserted-by":"publisher","first-page":"19719","DOI":"10.1038\/s41598-024-66265-5","volume":"14","author":"VJ Nehru","year":"2024","unstructured":"Nehru VJ, Vandakunnel MJ, Brammacharry U, Kannan T, Selvaraju S, Somasundaram S, et al. Risk assessment and transmission of fluoroquinolone resistance in drug-resistant pulmonary tuberculosis: a retrospective genomic epidemiology study. Sci Rep. 2024;14:19719. https:\/\/doi.org\/10.1038\/s41598-024-66265-5.","journal-title":"Sci Rep"},{"key":"2798_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13073-022-01084-2","volume":"14","author":"V Dreyer","year":"2022","unstructured":"Dreyer V, Mandal A, Dev P, Deshmukh R, Rodrigues C, Ajbani K, et al. High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region. Genome Med. 2022;14:95. https:\/\/doi.org\/10.1186\/s13073-022-01084-2.","journal-title":"Genome Med"},{"key":"2798_CR19","volume-title":"GLI model performance of the Hain Lifescience GenoType MTBDRsl VER 2.0 assay (second-line line probe assay) for detection of resistance to fluoroquinolones and second-line injectable drugs: consolidated data review","author":"Global Laboratory Initiative","year":"2018","unstructured":"Global Laboratory Initiative. GLI model performance of the Hain Lifescience GenoType MTBDRsl VER 2.0 assay (second-line line probe assay) for detection of resistance to fluoroquinolones and second-line injectable drugs: consolidated data review. Geneva: World Health Organization; 2018."},{"key":"2798_CR20","doi-asserted-by":"publisher","first-page":"1701354","DOI":"10.1183\/13993003.01354-2017","volume":"50","author":"P Miotto","year":"2017","unstructured":"Miotto P, Tessema B, Tagliani E, Chindelevitch L, Starks AM, Emerson C, et al. A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis. Eur Respir J. 2017;50:1701354. https:\/\/doi.org\/10.1183\/13993003.01354-2017.","journal-title":"Eur Respir J"},{"key":"2798_CR21","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/femsre\/fux011","volume":"41","author":"SM Gygli","year":"2017","unstructured":"Gygli SM, Borrell S, Trauner A, Gagneux S. Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives. FEMS Microbiol Rev. 2017;41:354\u201373. https:\/\/doi.org\/10.1093\/femsre\/fux011.","journal-title":"FEMS Microbiol Rev"},{"key":"2798_CR22","doi-asserted-by":"publisher","first-page":"e1001880","DOI":"10.1371\/journal.pmed.1001880","volume":"12","author":"KA Cohen","year":"2015","unstructured":"Cohen KA, Abeel T, Manson McGuire A, Desjardins CA, Munsamy V, Shea TP, et al. Evolution of extensively drug-resistant tuberculosis over four decades: whole genome sequencing and dating analysis of Mycobacterium tuberculosis isolates from KwaZulu-Natal. PLoS Med. 2015;12:e1001880. https:\/\/doi.org\/10.1371\/journal.pmed.1001880.","journal-title":"PLoS Med"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02798-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-026-02798-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02798-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:42:34Z","timestamp":1782920554000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-026-02798-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2798"],"URL":"https:\/\/doi.org\/10.1007\/s15010-026-02798-8","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"15 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}